
ImageneBio, Inc. (NASDAQ:IMA – Free Report) – Research analysts at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for shares of ImageneBio in a report issued on Friday, November 13th. HC Wainwright analyst A. He expects that the company will earn ($3.55) per share for the year. HC Wainwright currently has a “Strong-Buy” rating on the stock. The consensus estimate for ImageneBio’s current full-year earnings is ($3.47) per share. HC Wainwright also issued estimates for ImageneBio’s Q4 2026 earnings at ($1.07) EPS, Q1 2027 earnings at ($1.19) EPS, Q2 2027 earnings at ($1.34) EPS, Q3 2027 earnings at ($1.51) EPS, Q4 2027 earnings at ($1.69) EPS, FY2027 earnings at ($5.73) EPS, FY2028 earnings at ($5.35) EPS, FY2029 earnings at ($5.03) EPS and FY2030 earnings at ($4.95) EPS.
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImageneBio in a research note on Friday, September 25th. One investment analyst has rated the stock with a Strong Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $28.00.
Check Out Our Latest Analysis on ImageneBio
ImageneBio Stock Performance
NASDAQ:IMA opened at $3.20 on Tuesday. The stock has a 50-day simple moving average of $4.36 and a two-hundred day simple moving average of $5.47. ImageneBio has a 52-week low of $3.13 and a 52-week high of $8.25. The firm has a market capitalization of $36.32 million, a PE ratio of -0.70 and a beta of 0.83.
ImageneBio (NASDAQ:IMA – Get Free Report) last announced its earnings results on Monday, November 9th. The company reported ($0.91) EPS for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.08).
Institutional Trading of ImageneBio
A number of hedge funds and other institutional investors have recently modified their holdings of IMA. Trails Edge Capital Partners LP purchased a new position in shares of ImageneBio during the 2nd quarter valued at $1,663,824. Blue Owl Capital Holdings LP purchased a new stake in ImageneBio in the 2nd quarter worth $5,414,000. Cable Car Capital LP purchased a new stake in ImageneBio in the 2nd quarter worth $4,611,000. BlackRock Inc. purchased a new stake in ImageneBio in the 2nd quarter worth $797,000. Finally, Stonepine Capital Management LLC purchased a new position in shares of ImageneBio in the second quarter valued at about $539,044,000. 75.00% of the stock is owned by hedge funds and other institutional investors.
Key ImageneBio News
Investors following IMA have been watching these news items:
- Positive Sentiment: A recent report says ImageneBio’s third-quarter loss narrowed as its clinical trials advanced, offering a favorable update on financial performance and pipeline progress. ImageneBio stock: Q3 loss narrows as clinical trials advance
- Positive Sentiment: HC Wainwright maintained a Strong-Buy rating, a supportive analyst view, while issuing earnings estimates across 2026–2030. ImageneBio analyst coverage
- Negative Sentiment: The estimates underscore substantial ongoing losses: HC Wainwright forecasts a loss of $3.55 per share in FY2026 and $5.73 in FY2027, versus the cited current-year consensus loss of $3.47. Its quarterly estimates also project losses increasing through 2027, which could weigh on sentiment about funding needs and the path to profitability.
ImageneBio Company Profile
ImageneBio, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for immune-mediated and inflammatory diseases. Its research and development pipeline includes investigational medicines at various stages of clinical development; the company does not yet have marketed products. Key programs include IMG-007, an investigational antibody targeting OX40 being studied for atopic dermatitis and other inflammatory conditions, and IMG-004, an oral investigational BTK inhibitor for immune-mediated diseases.
Further Reading
- Five stocks we like better than ImageneBio
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for ImageneBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImageneBio and related companies with MarketBeat.com's FREE daily email newsletter.
